Past Studies
Our teams have undertaken a number of sponsored trials. For information on setting new clinical trials, please contact:
ktph.cru.admin@ktph.com.sg and
aow.johanan.sb@ktph.com.sg
Here are some examples of past studies:
VICTORIA Study Led by Dr Dinna Soon (Cardiology)
KTPH participated in the industry-sponsored clinical trial, VICTORIA, from 2016 to 2019. A total of 5050 chronic heart failure patients participated globally.
Results showed that subjects treated with Vericiguat in addition to standard of care had a 10% lower risk of cardiovascular death or first heart failure hospitalization. To date, no known therapies have been able to reduce the risk of hospitalization after a worsening event. Through this study, the novel Vericiguat could help bridge this gap.
News Article:
https://www.tctmd.com/news/win-vericiguat-high-risk-chronic-hf-patients-victoria
FIDELIO-DKD Study Led by A/Prof Sum Chee Fang (Diabetes Centre)
From 2015 to 2019, KTPH participated in the largest industry-sponsored Phase III clinical trial program to date in Chronic Kidney Disease (CKD) and Type II diabetes (T2D); with more than 13,000 patients participating worldwide. CKD is a deadly complication of T2D that affects 4 in 10 patients with T2D.
Results from this study showed that patients given the investigational drug, Finerenone, in addition to their standard of care, had a significant reduction in the time to first occurrence of kidney failure or renal death. Furthermore, when evaluating the composite time to first occurrence, Finerenone was also found to reduce the risk of non-fatal stroke, non-fatal myocardial infarction, cardiovascular (CV) death or heart failure hospitalization.
News Article:
https://sg.news.yahoo.com/bayer-finerenone-meets-primary-endpoint-110000889.html
PARADIGM-HF Led by Dr Ong Hean Yee (Cardiology)
PARADIGM-HF was an industry-sponsored clinical trial conducted in KTPH between 2009 and 2013. The trial tested a new heart failure medication that is now made available in Singapore after the clinical trial. With 29.9%* of deaths caused by Cardiovascular Diseases in 2014, the new medication is set to benefit many heart disease patients in the near future.
Spearheaded by Dr Ong Hean Yee in KTPH, the results of the trial which was published in 2014’s New England Journal of Medicine, demonstrated that patients who were given the new LCZ696 medication had a 20% and 21% reduced risk of death and hospitalization for heart failure respectively. The trial stopped 10 months earlier than intended because preliminary data showed overwhelming benefits the new medication could provide. Now available in the market, this is the first novel class of medication that is able to improve on mortality in heart failure since 1999.
KTPH’s participation in this trial was featured in numerous local newspapers such as The Straits Times, Berita Harian, The New Paper and My Paper in March and April 2016.
News Link:
http://www.straitstimes.com/singapore/health/spore-approves-new-heart-failure-drug
EMPA-REG OUTCOME Led by A/Prof Sum Chee Fang (Diabetes Centre)
In 2012, KTPH participated in EMPA-REG OUTCOME – an industry-sponsored trial conducted in 42 countries globally and involved a total of 7,028 diabetes patients between 2010 and 2013. Empagliflozin, the drug that was tested, was later described by The Straits Times to be ‘ a game-changer in the treatment of diabetes.
Results from the trial showed that type 2 diabetes patients had a lower rate of cardiovascular outcome when empagliflozin was prescribed in addition to the standard diabetes medication. The study was published in the New England Journal of Medicine. With strong evidence that empagliflozin can help with reducing cardiovascular risk, the new drug was submitted to the Health Sciences Authority (HAS) for registration, and has been approved for use in Singapore since December 2014.
News Link:
http://www.straitstimes.com/singapore/new-drug-may-lower-heart-risk-in-diabetics
ROCKET-AF (Atrial Fibrillation) & VTE Study Led by Dr Ong Hean Yee (Cardiology)
Rivaroxaban has been used in Singapore to prevent blood clots from forming in the veins of adults undergoing total hip or knee replacement surgery. In December 2013, the drug was given the approval to be used as an oral blood thinner by the Health Sciences Authority (HSA).
The ROCKET-AF clinical trial was conducted to investigate how effective Rivaroxaban is in reducing the risk of ischemic stroke in patients with atrial fibrillation as compared to conventional anticoagulation medication (warfarin). The trial recruited and followed up a total of 14,264 patients with atrial fibrillation globally between 2006 and 2010, of which 44 patients were from Singapore. The data, published in the New England Journal of Medicine in 2011, concluded that Rivaroxaban worked as well as warfarin in preventing stroke or systemic embolism.
In conjunction with ROCKET-AF, Dr Ong also led a team to investigate the incidences of venous thromboembolism (VTE), i.e. blood clots that form in veins, and the prescription of thromboprophylaxis amongst Asians. The cross-sectional study collected data from 1,103 KTPH patients who had undergone major orthopaedic or abdominal 2.1%. The study also found that patients over 75 years old are at higher risk of VTE. The findings have allowed KTPH to manage the risk of VTE, and to prevent the development of this fatal condition on our post-operative patients.
The outcome of the VTE study was reported in Shin Min Daily News, The New Paper and Lianhe Wanbao in April 2014, as well as in The Straits Times in June 2014.
News Link:
http://health.asiaone.com/health/health-news/singapore-study-debunks-blood-clot-myth
For information on setting new clinical trials, please contact:
ktph.cru.admin@ktph.com.sg &
yee.grace.pc@ktph.com.sg
